Why a Melanoma Vaccine Breakthrough Matters for Synovial Sarcoma
Merck and Moderna are making headlines after their personalized mRNA cancer vaccine entered Phase 3 clinical trials for melanoma. For most people, it is an exciting medical story. For the synovial sarcoma community, it is something more personal than that. What the Vaccine Is mRNA-4157,…
A new preclinical study published in Biomedicine and Pharmacotherapy by Tomohiro Miyazaki, Yudai Murayama, Naoki Oike, and colleagues from the Department of Pediatrics and Division of Orthopedic Surgery at Niigata University Graduate School of Medical and Dental Sciences, Japan, presents early but promising evidence for…
Kaela Graham-Bowman’s story reached national audiences this year when she was featured on 60 Minutes Australia. An Afghanistan veteran and nurse, Kaela was diagnosed with synovial sarcoma in 2020 at age 28, while working as an oncology nurse herself. What followed was a six-year fight…
Synovial Sarcoma Foundation Welcomes Julie Kramer as Community Engagement & Partnerships Manager
Current Patient to Drive Relationships and Support for the Synovial Sarcoma Community [Philadelphia, PA] – 12/12/25 – The Synovial Sarcoma…
Arizona Pioneers New Immune Therapy for Synovial Sarcoma Treatment
In a groundbreaking advancement in cancer treatment, a patient with synovial sarcoma in Arizona has become the first in the…
Revolutionary Insights Unveiled in Latest Synovial Sarcoma Research
A landmark study just published in Nature Communications finally pinpointed the exact “cell of origin” for synovial sarcoma — a rare, primitive…
2025 Connective Tissue Oncology Society
The Synovial Sarcoma Foundation is excited to share that we are on site this week at the 2025 Connective Tissue Oncology Society…
Rise in Early-Onset Cancers: More Diagnoses, Not Always More Disease
Not every detected cancer is clinically meaningful. For younger patients, especially, this can mean confronting a diagnosis that may never…
Dr. Theodore W. Laetsch, Synovial Sarcoma Foundation Board Member, Receives $1 Million Grant to Advance Rare Tumor Studies
The Synovial Sarcoma Foundation is pleased to highlight a significant milestone at the Children’s Hospital of Philadelphia (CHOP), where pediatric…
Innovative Approach Shows Promise Against Synovial Sarcoma Using Protein-Blocking Drugs
The Synovial Sarcoma Foundation is dedicated to supporting cutting-edge research that advances treatment options for this rare and aggressive cancer.…
New Market Insights Highlight Growth in Synovial Sarcoma Treatments
The Synovial Sarcoma Foundation is committed to staying informed on the latest research and developments in this rare and aggressive…
Tumor Board Continues to Grow with New Members to Advance Breakthrough Treatments for Synovial Sarcoma Patients
We are proud to share that the Tumor Board now includes 42 participating institutions, strengthening our collective expertise and reach.…
